Jane Gartlon

GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer’s Disease Brain and Improves Cognitive Performance in Preclinical Models

Andrew D. Medhurst, A.R. Atkins, I.J.M. Beresford et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 301 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism

Laura W. Harris, Trevor Sharp, Jane Gartlon et al. · European Journal of Neuroscience · 2003 · 162 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease

Malcolm C. Roberts, Ioanna Sevastou, Yoichi Imaizumi et al. · Acta Neuropathologica Communications · 2020 · 133 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity

Declan N.C. Jones, Jane Gartlon, Frederick B. Parker et al. · Psychopharmacology · 2001 · 105 citations

Medicine, Pharmacology, Physiology +7

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

Marie L. Woolley, Helen J. Carter, Jane Gartlon et al. · European Journal of Pharmacology · 2008 · 98 citations

Medicine, Neuroscience, Pharmacology +14